| Date Filed | Type | Description |
| 10/12/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/06/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 2,788,620 options to buy
@ $0.001, valued at
$2.8k
Granted 1,394,310 options to buy
@ $5.38, valued at
$7.5M
Granted 1,690,014 options to buy
@ $8.877, valued at
$15M
|
|
| 10/06/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.9% stake in Vistagen Therapeutics, Inc. |
| 10/05/2023 |
SC 13G
| Point72 Asset Management, L.P. reports a 5.6% stake in Vistagen Therapeutics, Inc. |
| 10/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 10/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/02/2023 |
8-K
| Quarterly results |
| 09/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/23/2023 |
4
| Anderson Cynthia Lynn (CFO) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 8,333 options to buy
@ $5.34, valued at
$44.5k
|
|
| 08/23/2023 |
3
| Anderson Cynthia Lynn (CFO) has filed a Form 3 on Vistagen Therapeutics, Inc. |
| 08/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
SC 13G
| COMMODORE CAPITAL LP reports a 19.7% stake in Vistagen Therapeutics, Inc. |
| 08/09/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Bought 775,756 shares
@ $23.153, valued at
$18M
|
|
| 08/09/2023 |
3
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 3 on Vistagen Therapeutics, Inc. |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 0% stake in VistaGen Therapeutics, Inc. |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/05/2023 |
4
| Singh Shawn (CEO) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 167 shares
@ $1.5895, valued at
$265.4 |
|
| 07/05/2023 |
4
| Adler Reid G. (CHIEF LEGAL OFFICER) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 167 shares
@ $1.5895, valued at
$265.4 |
|
| 07/05/2023 |
4
| DOTSON JERROLD DUANE (VP, CFO) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 167 shares
@ $1.5895, valued at
$265.4 |
|
| 06/30/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/28/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 06/28/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|